Cargando…

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature

Background: Anemia treatment in infants with advanced or chronic kidney disease (CKD) represents an important challenge to nephrologists. The use of darbepoetin alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human erythropoietin in older children and in adults with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Libudzic-Nowak, Anna Maria, Cachat, Francois, Pascual, Manuel, Chehade, Hassib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305342/ https://www.ncbi.nlm.nih.gov/pubmed/30619793 http://dx.doi.org/10.3389/fped.2018.00398

Ejemplares similares

Transient Arterial Hypertension Induced by Gonadotropin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
por: Sifaki, Loukia, et al.
Publicado: (2019)

Re: Microalbuminuria in Normal Korean Children
por: Cachat, Francois, et al.
Publicado: (2012)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells
por: Andreucci, Michele, et al.
Publicado: (2021)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Hydronephrosis caused by kidney malrotation
por: Divjak, Natalie, et al.
Publicado: (2021)

Serum NGAL, BNP, PTH, and albumin do not improve glomerular filtration rate estimating formulas in children
por: Mouron-Hryciuk, Julie, et al.
Publicado: (2021)

A Rare Sparkle: A Case of Calcified Kidneys in a Young Infant With Renal Failure
por: Mittal, Aliza, et al.
Publicado: (2023)

Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009)

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
por: Schaefer, Franz, et al.
Publicado: (2015)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure
por: André, Jean-Luc, et al.
Publicado: (2007)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Renal Programming by Transient Postnatal Overfeeding: The Role of Senescence Pathways
por: Juvet, Christian, et al.
Publicado: (2020)

A novel LAMB2 gene mutation associated with a severe phenotype in a neonate with Pierson syndrome
por: Zemrani, Boutaina, et al.
Publicado: (2016)

Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
por: Egrie, J, et al.
Publicado: (2002)

Two new families with hereditary minimal change disease
por: Chehade, Hassib, et al.
Publicado: (2013)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports
por: Chehade, Hassib, et al.
Publicado: (2021)

Aldosterone defects in infants and young children with hyperkalemia: A single center retrospective study
por: Liu, Xu, et al.
Publicado: (2023)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
por: Chen, Nan, et al.
Publicado: (2022)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
por: Deger, Melike, et al.
Publicado: (2012)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
por: Platzbecker, U, et al.
Publicado: (2017)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
por: van den Oever, Francisca Johanna, et al.
Publicado: (2020)

Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
por: Tani, Junya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4puaccq2ruv0b74a6hbr6e67i